The antifungal voriconazole is effective for the treatment of invasive fungal infections in immunocompromised patients. A serious adverse reaction is QT interval prolongation, which may precede life-threatening arrhythmias, such as torsades de pointes. Although ventricular arrhythmias are mentioned as a possible adverse effect of voriconazole, thus far, the incidence and clear recommendations for QT follow-up have not been published. This prospective observational study aimed at describing the incidence of voriconazole induced- QT interval prolongation in the pediatric population and determine the risk factors for this phenomenon.

Inclusion Criteria:

• oral or IV treatment with voriconazole

Exclusion Criteria:

• No data prior to initiation of voriconazole treatment on QT interval (baseline ECG)
• Renal insufficiency or dialysis treatment

Children aged 0-20 years treated with oral or IV voriconazole at the Schneider Children's Medical Center from Oct 31st 2016.